Skip to main content

Table 2 Cox proportional Univariate analysis for Baseline Characteristics of Patients with or without Severe Hepatotoxicity

From: Risk factors of severe hepatotoxicity among HIV-1 infected individuals initiated on highly active antiretroviral therapy in the Northwest Region of Cameroon

Characteristics of study the population Level Univariate Analysis    
   No N (%) Yes N (%) OR(95%CI) P
Age group (Years) <30 14 (51.9) 1 3(48.1) 1 0.02
  30–40 33 (76.7) 10 (23.3) 0.15 (0.03–0.65)  
  >40 25 (83.3) 5 (16.7) 0.40 (0.11–1.47)  
Gender Male 28 (59.6) 19 (40.4) 1 0.04
  Female 44 (83.0) 9 (17.0) 0.26 (0.89–5.28)  
Body Mass Index Normal 26 (83.9) 5 (16.1) 1 0.02
  Low 29 (61.7) 18 (38.3) 0.38 (0.04–3.35)   
  Overweight 6 (85.7) 1 (14.3) 0.30 (0.11–0.78)  
  Obese 11 (73.3) 4 (26.7) 0.20 (0.02–1.79)  
Level of Education None 4 (80.0) 1 (20.0) 1 0.89
  Primary 38 (74.5) 13 (25.5) 1.37 (0.14–13.38)  
  Secondary 26 (68.4) 12 (31.6) 1.84 (0.19–18.33)  
  Tertiary 4 (66.7) 2 (33.3) 2 (0.13–31.96)  
Monthly income < 50,000 51 (66.2) 26 (33.8) 1 0.01
  >50,000 21 (91.3) 2 (8.7) 0.18 (0.04–0.86)  
Alcohol intake No 33 ( 75) 11 (25 ) 1 0.07
  Yes 39 (69.6 ) 17 (30.4) 0.40 (0.11–1.47)  
Cigarette or tobacco intake No 56 (76.7) 17 (23.3) 1 0.09
  Yes 16 (59.3) 11 (40.7) 2.26 (0.88–5.80)  
Year of diagnosis < 1 Year 61 (72.6) 23 (27.4) 1 0.91
  1–3 Years 3 (75.0) 1 (25.0) 0.88 (0.09–8.94)  
  >3 Years 8 (66.7) 4 (33.3) 1.33 (0.36–4.83)  
CD4 Count values in cells/μl <200 37 (64.9) 20 (35.1) 1 0.06
  >200 35 (81.4) 8 (18.6) 0.42 (0.161.08)  
WHO stages Stage 1 8 (57.1) 6 (42.9) 1 0.27
  Stage2 32 (71.1) 13 (28.9) 0.54 (0.16–1.87)  
  Stage 3 30 (81.1) 7 (18.9) 0.31 (0.08–1.19)  
  Stage 4 2 (50.0) 2 (50.0) 1.33 (0.14–12.37)  
Name of ARV regimen TDF+3TC+EFV 46 (73.0) 18 (27.0) 1 0.01
  AZT+3TC+ EFV 20 (90.9) 2 (9.1) 0.25 (0.05–1.18)  
  AZT+3TC+NVP 6 (42.9) 8 (57.1) 2.86 (0.90–9.04)  
  1. 3TC: Lamivudine, AZT: Zidovudine, BMI: Body mass index, EFV: Efavirenz, NVP: Nevirapine; TDF: Tenofovir